Atea Pharmaceuticals, Inc. (AVIR) vs DiaMedica Therapeutics, Inc. (DMAC)

Atea Pharmaceuticals, Inc. and DiaMedica Therapeutics, Inc. are both Biotechnology companies. Atea Pharmaceuticals, Inc. and DiaMedica Therapeutics, Inc. are of similar size ($422.2M and $414.7M). Across the 8 metrics below, Atea Pharmaceuticals, Inc. leads on 6 and DiaMedica Therapeutics, Inc. on 2.

Valuation

Metric AVIR DMAC Biotechnology median
P/E n/m n/m 7.88
P/S 1.18 n/m 11.47
P/B 2.03 11.16 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.55 n/m 10.73
Earnings yield (40.23%) (9.07%) (28.84%)
Free cash flow yield (132.88%) (7.37%) (23.03%)

Profitability

Metric AVIR DMAC Biotechnology median
Gross margin 0.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (58.14%) (114.62%) (57.72%)
Return on assets (52.99%) (98.18%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AVIR DMAC Biotechnology median
Revenue growth (TTM) — — 5.64%
EPS growth (last fiscal year) 3.00% (16.67%) —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AVIR DMAC Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.13 6.72 4.73
Net debt to EBITDA 1.63 1.70 0.96

Dividend

Metric AVIR DMAC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AVIR DMAC Biotechnology median
Market cap 414.66m 422.24m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack